FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010134510> ?p ?o ?g. }

• W3010134510 endingPage "210" @default.
• W3010134510 startingPage "210" @default.
• W3010134510 abstract "The approvals of immune checkpoint inhibitors for several cancer types and the rapidly growing recognition that T cell-based immunotherapy significantly improves outcomes for cancer patients led to a re-emergence of cancer vaccines, including dendritic cell (DC)-based immunotherapy. Blood and tissue biomarkers to identify responders and long-term survivors and to optimize cost and cost-effectiveness of treatment are greatly needed. We wanted to investigate whether blood eosinophilia is a predictive biomarker for patients with solid tumors receiving vaccinations with DCs loaded with autologous tumor-RNA.In total, 67 patients with metastatic solid tumors, who we treated with autologous monocyte-derived DCs transfected with total tumor mRNA, were serially analyzed for eosinophil counts and survival over the course of up to 14 years. Eosinophilic counts were performed on peripheral blood smears.Up to 87% of the patients treated with DC-based immunotherapy experienced at least once an eosinophilia of ≥ 5% after initiation of therapy; 61 % reached levels of ≥ 10% eosinophils, and 13% of patients showed eosinophil counts of 20% or above. While prevaccination eosinophil levels were not associated with survival, patients with blood eosinophilia at any point after initiation of DC-based immunotherapy showed a trend towards longer survival. There was a statistically significant difference for the patients with eosinophil counts of 20% or more (p = 0.03). In those patients, survival was prolonged to a median of 58 months (range 2-111 months), compared to a median of 20 months (range 0-119 months) in patients with lower eosinophil counts. In 12% of the patients, an immediate increase in eosinophil count of at least 10 percentage points could be detected after the first vaccine, which also appeared to correlate with survival (65 vs. 24 months; p = 0.06).Blood eosinophilia appears to be an early, on-therapy biomarker in patients with solid tumors undergoing vaccination with RNA-transfected DC, specifically autologous tumor mRNA-transfected DC vaccines, and it correlates with long-term patient outcome. Eosinophilia should be systematically investigated in future trials." @default.
• W3010134510 created "2020-03-13" @default.
• W3010134510 creator A5004934835 @default.
• W3010134510 creator A5009718678 @default.
• W3010134510 creator A5019149733 @default.
• W3010134510 creator A5054793680 @default.
• W3010134510 creator A5064778812 @default.
• W3010134510 creator A5071369473 @default.
• W3010134510 date "2020-03-01" @default.
• W3010134510 modified "2023-09-23" @default.
• W3010134510 title "Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA" @default.
• W3010134510 cites W1499815917 @default.
• W3010134510 cites W1581074935 @default.
• W3010134510 cites W1591392487 @default.
• W3010134510 cites W1834154263 @default.
• W3010134510 cites W1936755024 @default.
• W3010134510 cites W1964612175 @default.
• W3010134510 cites W1967715962 @default.
• W3010134510 cites W1977096306 @default.
• W3010134510 cites W1998756236 @default.
• W3010134510 cites W2007026865 @default.
• W3010134510 cites W2034099314 @default.
• W3010134510 cites W2037801848 @default.
• W3010134510 cites W2040329743 @default.
• W3010134510 cites W2046505430 @default.
• W3010134510 cites W2064329354 @default.
• W3010134510 cites W2076246627 @default.
• W3010134510 cites W2079310034 @default.
• W3010134510 cites W2083310288 @default.
• W3010134510 cites W2084472394 @default.
• W3010134510 cites W2101439161 @default.
• W3010134510 cites W2102473788 @default.
• W3010134510 cites W2107863654 @default.
• W3010134510 cites W2108583660 @default.
• W3010134510 cites W2118999172 @default.
• W3010134510 cites W2122895790 @default.
• W3010134510 cites W2123520395 @default.
• W3010134510 cites W2130754261 @default.
• W3010134510 cites W2133358020 @default.
• W3010134510 cites W2138345681 @default.
• W3010134510 cites W2148962946 @default.
• W3010134510 cites W2156329268 @default.
• W3010134510 cites W2203287277 @default.
• W3010134510 cites W2282962877 @default.
• W3010134510 cites W2291366206 @default.
• W3010134510 cites W2494289731 @default.
• W3010134510 cites W2581911737 @default.
• W3010134510 cites W2606303171 @default.
• W3010134510 cites W2607114575 @default.
• W3010134510 cites W2607153010 @default.
• W3010134510 cites W2609112769 @default.
• W3010134510 cites W2727856228 @default.
• W3010134510 cites W2766930471 @default.
• W3010134510 cites W2784346742 @default.
• W3010134510 cites W2785409534 @default.
• W3010134510 cites W2793988379 @default.
• W3010134510 cites W2797967795 @default.
• W3010134510 cites W2807176127 @default.
• W3010134510 cites W2807314560 @default.
• W3010134510 cites W2809886276 @default.
• W3010134510 cites W2894440316 @default.
• W3010134510 cites W2896041340 @default.
• W3010134510 cites W2896948312 @default.
• W3010134510 cites W2902030323 @default.
• W3010134510 cites W2909453638 @default.
• W3010134510 cites W2909762028 @default.
• W3010134510 cites W2912125303 @default.
• W3010134510 cites W2912735280 @default.
• W3010134510 cites W2913135237 @default.
• W3010134510 cites W2914541909 @default.
• W3010134510 cites W2925090624 @default.
• W3010134510 cites W2927403340 @default.
• W3010134510 cites W2932352133 @default.
• W3010134510 cites W2963084350 @default.
• W3010134510 cites W2981922825 @default.
• W3010134510 cites W2982130496 @default.
• W3010134510 cites W3299410 @default.
• W3010134510 doi "https://doi.org/10.3390/pharmaceutics12030210" @default.
• W3010134510 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7150785" @default.
• W3010134510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32121531" @default.
• W3010134510 hasPublicationYear "2020" @default.
• W3010134510 type Work @default.
• W3010134510 sameAs 3010134510 @default.
• W3010134510 citedByCount "5" @default.
• W3010134510 countsByYear W30101345102020 @default.
• W3010134510 countsByYear W30101345102021 @default.
• W3010134510 countsByYear W30101345102022 @default.
• W3010134510 countsByYear W30101345102023 @default.
• W3010134510 crossrefType "journal-article" @default.
• W3010134510 hasAuthorship W3010134510A5004934835 @default.
• W3010134510 hasAuthorship W3010134510A5009718678 @default.
• W3010134510 hasAuthorship W3010134510A5019149733 @default.
• W3010134510 hasAuthorship W3010134510A5054793680 @default.
• W3010134510 hasAuthorship W3010134510A5064778812 @default.
• W3010134510 hasAuthorship W3010134510A5071369473 @default.
• W3010134510 hasBestOaLocation W30101345101 @default.
• W3010134510 hasConcept C121608353 @default.
• W3010134510 hasConcept C126322002 @default.

• next